NASDAQ$OFIX

Orthofix Medical Inc · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Briefing

Orthofix reported a strong third quarter with significant revenue growth and progress in merger synergy realization.

Orthofix reported net sales of $184.0 million, a 61% increase on a reported basis and an 8% increase on a pro forma basis. EPS was $(0.77), and adjusted EPS was $0.07. The company saw strong growth across multiple business segments and product lines and is focused on driving shareholder value via profitable growth and merger synergy realization.

  • Net sales increased by 61% on a reported basis and 8% on a pro forma basis, reaching $184.0 million.
  • Bone Growth Therapies grew by 15%, marking three consecutive quarters of double-digit net sales increases.
  • U.S. spinal implants, biologics, and enabling technologies sales grew by 7% on a pro forma basis.
  • Adjusted EBITDA was $13.5 million, representing 7.3% of sales, and a 36% sequential growth over the second quarter of 2023.

Headline financials

Total Revenue

$184M

Previous: $114M+61.4%
EPS (adj)

$0.07

Previous: $0.13-46.2%
Capital Expenditures

-$45.7M

Previous: -$16.2M-182.8%
Free Cash Flow

-$74.6M

Previous: -$26.9M-177.4%
Net Income

-$28.9M

Previous: -$10.7M-169.3%
Operating Income

-$24.4M

Previous: -$5.79M-322.5%
Gross Profit

$120M

Previous: $83.4M+43.6%
Cash & Equivalents

$33.7M

Previous: $51.7M-34.8%
Total Assets

$906M

Previous: $450M+101.4%
R&D Expense

$18.6M

No prior period
Stock-Based Comp

$6.27M

Previous: $4.73M+32.7%

Revenue & EPS history

Orthofix · Revenue · Quarterly

$184M

Q3 2023+61.4%vs Q3 2022
Beat estimate in 10 of 14 quarters(71%)
ActualEstimate

Revenue by segment

Orthofix · $83.1M total across 2 segments · Q3 2023

  • Bone Growth Therapies
    $53.4M+14.8%
  • Global Limb Reconstruction
    $29.7M+6.8%

Forward guidance

The Company expects the following financial results for the year ended December 31, 2023. Full year net sales between $739 million and $744 million and full year adjusted EBITDA between $42 million and $46 million.

Tailwinds

  • Full year net sales are expected to be between $739 million and $744 million.
  • Represents a year-over-year increase of 60.4% to 61.5% on a reported basis.
  • Represents an increase of 5.4% to 6.2% on a pro forma basis.
  • Full year adjusted EBITDA is expected to be between $42 million and $46 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

-0.9%

Avg return

Earnings day

-2.6%

Avg return

5 days after

-3.4%

Avg return

30 days after

48%

31 / 65 earnings

Positive

+20.3%

Q2 2014

Best reaction

-18.5%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+3.8%-2.8%-13.8%
Q4 2025-7.0%-0.4%-13.2%
Q3 2025-7.4%-6.8%-1.0%
Q1 2025-10.8%-10.6%-20.9%
Q4 2024-3.5%-4.2%-11.0%
Q3 2024+5.5%+4.6%+1.2%
Q2 2024+13.8%+10.8%+16.7%
Q1 2024+10.7%+8.8%+0.6%
Q4 2023+8.1%+7.1%+8.6%
Q3 2023-12.5%-20.2%-3.2%
Q2 2023+9.9%+7.6%+1.3%
Q1 2023+1.0%-2.3%+6.7%
Q4 2022-7.7%-13.2%-15.5%
Q3 2022-2.2%+4.1%+30.5%
Q2 2022-6.6%-8.8%-20.9%
Q1 2022-10.5%-14.3%-11.6%
Q4 2021+4.0%+3.5%+0.4%
Q3 2021-5.9%-10.9%-18.6%
Q2 2021+8.9%+4.1%+12.4%
Q1 2021+0.5%-2.0%-8.7%
Q4 2020+0.6%-0.5%-7.3%
Q3 2020+5.2%+13.6%+10.8%
Q2 2020+4.5%+4.6%-13.4%
Q1 2020-1.9%-6.9%+3.9%
Q4 2019-18.5%-21.5%-40.9%
Q3 2019-16.8%-17.0%-9.6%
Q2 2019+0.1%+2.6%-5.5%
Q1 2019-2.6%-0.3%-10.9%
Q4 2018-8.5%-10.0%-14.8%
Q3 2018+7.4%+8.8%+4.1%
Q2 2018-15.1%-11.9%-12.1%
Q1 2018-13.4%-14.6%-10.5%
Q4 2017+6.4%+4.6%+8.4%
Q3 2017+8.8%+5.1%+9.6%
Q2 2017+9.9%+6.8%+12.3%
Q1 2017+1.4%+3.8%+8.2%
Q4 2016-6.1%-4.8%+2.6%
Q3 2016-3.8%-6.8%-1.5%
Q2 2016-10.4%-10.5%-4.8%
Q1 2016+0.4%
Q4 2015+2.8%
Q3 2015+14.4%
Q2 2015+13.8%
Q1 2015+0.4%
Q4 2014-10.8%
Q3 2014+20.3%
Q2 2014+20.3%
Q1 2014+4.2%
Q4 2013+14.1%
Q3 2013+1.1%
Q2 2013-0.8%
Q1 2013-16.4%
Q4 2012-4.9%
Q3 2012-2.8%
Q2 2012+4.5%
Q1 2011-0.7%
Q1 2012+1.0%
Q1 2010-4.8%
Q4 2011-4.8%
Q4 2009-4.8%
Q3 2010-7.4%
Q3 2011-7.4%
Q4 2010-9.5%
Q2 2010-9.5%
Q2 2011-9.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro